SCHOTT establishes stand-alone company for its pharma business
SCHOTT has established a stand-alone company for its pharma business under the name SCHOTT Pharma AG & Co. KGaA to advance its growth strategy.
"By creating a separate legal entity for our pharma business, we are generating new opportunities to expedite our profitable growth," says SCHOTT CEO Dr. Frank Heinricht, "Pharma will remain an integral part of SCHOTT in the future. With this move, we are creating more room for organic and inorganic growth and further potential investments towards becoming climate neutral by 2030."
The company is investing a three-digit million Euro figure to meet worldwide demand. A new production facility for prefillable polymer syringes has started operations in Germany, and a new plant for glass syringes is currently under construction in Hungary. The company broke ground on new production buildings in China and is planning to triple its capacity for high-quality sterile vials in the USA.
Image: SCHOTT Pharma produces around 13 billion products per year. Photo: SCHOTT/Oana Szekely